fda bpc-157 compounding category 2 list Peptide Update: Removal & PCAC Dates The FDA Is Reconsidering Its
Description
It has been shown to promote gut health, reduce inflammation, and potentially address conditions like inflammatory bowel disease and leaky gut syndrome
If your first test shows borderline or low levels, retest 4-6 weeks later to confirm
Review of epidemiological and preclinical studies
The large number of promising clinical studies with IN-OXT has fueled a lot of excitement about its therapeutic potential, but many IN-OXT studies with similar study designs to those discussed above have found little to no observed effects on social cognitive impairments
